Kane Biotech Inc. (CVE:KNE – Get Free Report) shares reached a new 52-week low on Tuesday . The stock traded as low as C$0.03 and last traded at C$0.03, with a volume of 1800 shares traded. The stock had previously closed at C$0.03.
Kane Biotech Stock Down 16.7%
The company has a debt-to-equity ratio of -135.17, a current ratio of 0.45 and a quick ratio of 0.39. The firm has a market capitalization of C$5.13 million, a P/E ratio of -2.50 and a beta of 0.97. The business has a 50 day moving average price of C$0.03 and a 200 day moving average price of C$0.04.
Kane Biotech Company Profile
Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.
See Also
- Five stocks we like better than Kane Biotech
- AI Fears Hit Nebius Stock, But Has the Growth Thesis Changed?
- These 3 Dividend Stocks Could Boost Your Income This July
- Rocket Lab Defies Gravity With $8B Buyout
- Even CEOs Need Cash: Insider Selling Is Not the Only Signal in AI Stocks
Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
